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Introduction
Gastric cancer (GC) has one of the highest rates of neoplasia- 
related mortality worldwide (1). Chronic inflammation after infec-
tion with Helicobacter pylori is an established risk factor for the 
most common or “intestinal-type” GC (2), initiating progression 
to atrophic gastritis, intestinal metaplasia, and adenocarcinoma 
(2). Nevertheless, causal mechanisms linking inflammation to GC 
progression remain incompletely understood. GC is believed to be 
of epithelial origin, deriving clonally from gastric epithelial cells 
(GECs) or their progenitors (3, 4). Therefore, elucidation of factors 
that counteract the immune-related premalignant transformation 
of GECs (2) is of high priority for the advancement of GC therapies 
and improved survival.
Gastrokines (GKNs) are small (~18-kDa) proteins belonging to 
the BRICHOS protein superfamily, characterized by an approxi-
mately 100–amino acid BRICHOS domain, with established links 
to inflammatory disease, dementia, and cancer (5, 6). While all 
BRICHOS proteins are secreted or processed to generate secreted 
mature peptides, GKNs are unique in being almost exclusively 
expressed within, and secreted by, mucus-producing epithelial 
cell lineages of the stomach (6–9). The 3 GKNs are encoded by 
a tightly linked gene cluster on human chromosome 2p13.3 and 
show broad evolutionary conservation in mammals and higher 
vertebrates (6, 10). GKN1 and GKN2 were identified in differen-
tial expression screens as novel genes downregulated in GC (7, 8, 
11). The recently discovered GKN3 was found in a bioinformatic 
scan for novel BRICHOS proteins. Mouse Gkn3, in contrast to the 
other GKNs, is overexpressed in atrophic gastritis associated with 
H. pylori infection (9, 10). While broadly functional in mammals, 
human GKN3 persists only as a nonexpressed pseudogene (9, 10).
Abundantly expressed in surface mucus cells (SMCs) of 
the normal human stomach, GKN1 and GKN2 show coordinate 
downregulation in H. pylori infection, frequent loss of expression 
in gastric adenocarcinoma, and silencing in tumor cell lines (8). 
Conversely, an expression microarray study identified GKN2 as 
the most upregulated gene in the gastric transcriptome after erad-
ication of H. pylori and resolution of mucosal inflammation (12). 
These observations argue that GKNs and, in particular, GKN2, 
function either as homeostatic regulators of mucosal immunity 
and/or as stomach-specific tumor-suppressor genes (TSGs). Bio-
activities attributed to GKNs include growth suppression, inhibi-
tion of epithelial-to-mesenchymal transition, migration, and inva-
sion of tumor cells (reviewed in ref. 6). While ostensibly supportive 
of TSG or anticancer roles, these functional observations derive 
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QRT-PCR revealed progressive loss of Gkn2 mRNA from the proxi-
mal or corpus stomach, commencing between 7 days and 2 months 
after infection (MPI) with mouse-adapted H. pylori Sydney strain 
1 (SS1), with more pronounced loss (in whole stomach) at 12 MPI 
(Figure 1E). Similarly, decreased Gkn2 mRNA expression occurred 
in stomachs of mice with genetic induction of gastric inflamma-
tion (stomach-overexpressing H+K+ATPase β subunit [Atp4b] pro-
moter Gm-CSf transgenic [Gm-CSfTg] mice), atrophy/metaplasia/
hypertrophy (HKβ–/– mice), and tumorigenesis (gp130F/F mice; HKβ 
promoter IL1β transgenic [IL1βTg mice]) (Figure 1F). Gkn2 mRNA 
expression was unchanged in the distal (antral) stomach during 
the early stages of H. pylori infection (7 days and 2 MPI; Figure 1E) 
but strongly downregulated in antral tumors of gp130F/F mice (Fig-
ure 1F). Therefore, GKN2/Gkn2 expression levels were inversely 
correlated with (H. pylori–related) gastric pathology. These results 
reveal conservation of GKN2 loss in GC pathogenesis in humans 
and mice, thereby validating a mouse genetic approach to investi-
gate GKN2 loss in vivo.
Targeted deletion of the mouse Gkn2 locus. We derived a Gkn2 
knockout allele using VelociGene embryonic stem cell lines 
(Knockout Mouse Project) in which Gkn2-coding exons were 
replaced with a lacZ reporter and floxed neomycin selection cas-
sette. The neomycin cassette was excised by crossing Gkn2+/– hete-
rozygotes with germline-specific Cre-recombinase–deleter trans-
genic mice (20), and the resulting progeny were mated to obtain 
homozygous mutants (Figure 2, A and B). Homozygous Gkn2–/– 
mice were functionally null, showing a complete absence of GKN2 
protein in gastric lysates, but expressed normal levels of GKN1 
and GKN3 proteins (Figure 2C). Additionally, Gkn2–/– mice showed 
normal fertility, viability, and postnatal survival (Supplemental 
Tables 1 and 2 and Supplemental Figure 3). To identify cell lineages 
primarily affected by targeting the Gkn2 locus, we histochemically 
assessed lacZ reporter gene (β-gal) expression by staining whole-
mount stomachs with X-gal (Supplemental Methods). Consistent 
with the pattern of endogenous Gkn2 expression (Figure 1D), we 
observed intense β-gal expression in the corpus and antral-pyloric 
mucosa of Gkn2+/– mice (Figure 2, D and E), which ceased abruptly 
at the proximal limiting ridge at the corpus/forestomach (Figure 
2F) and pyloric/duodenal (Figure 2G) junctions, respectively. His-
tological analysis showed specific localization of β-gal expression 
to SMCs of the corpus (Figure 2, H and I) and antrum (Figure 2, 
J and K). Double staining in Gkn2+/– stomachs confirmed over-
lapping distribution of GKN2 and β-gal in SMCs (Figure 2, L–N). 
Therefore, expression of this Gkn2-lacZ reporter/null allele mir-
rors that of endogenous GKN2 protein, suggesting that gastric 
SMC is the only lineage autonomously affected by GKN2 loss of 
function in Gkn2–/– mice.
Gkn2–/– mice show impairment of gastric epithelial differentiation 
that does not progress to malignant disease. Stomachs from 6-, 12-, 
and 30-week-old Gkn2–/– mice were examined by standard histo-
pathology. Although cell-autonomous TSG roles have been long 
suspected of GKN family proteins (6), Gkn2–/– mice showed no 
evidence of spontaneous gastric tumors to support this supposi-
tion. Gkn2–/– mice presented with clear abnormalities of the corpus 
mucosa, including focal hypertrophic lesions, which were evident 
macroscopically and histologically. Lesions were first apparent at 
6 weeks of age and persisted, but did not increase in severity, in 
mostly from studies in transformed cell lines and, thus, have lim-
ited in vivo relevance. Modes of action of GKNs are poorly under-
stood, with cognate receptors and signal transduction pathways 
remaining elusive (see commentary in ref. 6). However, reports of 
a gastric secreted GKN2/trefoil factor 1 (TFF1) heterodimer (13, 
14) have suggested that GKN2 might act via homeostatic and/or 
tumor-suppressor activities of TFFs. Current literature implicates 
GKN2 loss as a determinant of GC pathogenesis, yet evidence of 
a causal role is lacking. Despite their likely clinical importance, 
none of the GKNs have been tested functionally in mouse genetic 
models. As such, physiological and pathological roles of GKN2 
(and of other GKNs) remain unsubstantiated in vivo.
To address the impact of GKN2 loss on GC pathogenesis in 
vivo, here we report the generation and phenotype analysis of Gkn2 
knockout mice. Our studies show that GKN2 has antiinflammatory 
activity in the stomach sufficient to restrain progression of cytokine- 
driven gastric tumorigenesis and H. pylori infection–related prema-
lignancy. Moreover, transgenic expression of human GKNs in a val-
idated gastric tumor model restrains pathological progression. The 
mechanism for GKN2 activity involves expansion and activation 
of suppressive myeloid cells and inhibition of antigen-presenting 
cells (APCs), including macrophages and DCs, leading to, leading 
to attenuated mucosal Th1 immunity. These studies reveal anti-
inflammatory and tumor inhibitory roles for GKN2 and elucidate 
GKN2 loss as a key event underlying GC progression.
Results
Conserved GKN2 expression loss in human and mouse GC progres-
sion. Human GKN2 and mouse Gkn2 are highly conserved in their 
genomic organization, intron/exon structure, and genetic linkage to 
other GKN paralogs (Supplemental Figure 1; supplemental material 
available online with this article; doi:10.1172/JCI82655DS1) and 
are thus predicted to show similar regulation in vivo. Mouse genetic 
models have revealed key mechanisms underlying the premalig-
nant transformation of GECs (15–19) and collectively reproduce 
many of the histopathologic features of human GC progression 
(Supplemental Figure 2). To confirm clinical relevance and estab-
lish a rationale for using a mouse genetic approach to GKN2 loss, 
we compared GKN2 expression in human and mouse GC patho-
genesis. Quantitative RT-PCR (QRT-PCR) revealed progressive 
loss of GKN2 mRNA in human gastric epithelial tissues from indi-
viduals with H. pylori infection/gastritis (fold change –3.61 ± 0.56; 
P < 0.001) and intestinal metaplasia (fold change –10.62 ± 3.51; 
P < 0.001) relative to normal (disease-free) controls; GKN2 mRNA 
was either marginally expressed or undetected in the majority of 
gastric tumors (GC; fold change –84,223 ± 31,909; P < 0.001; Fig-
ure 1A). Loss of GKN2 mRNA was also reflected at the protein level. 
Immunohistochemical staining revealed abundant GKN2 expres-
sion in SMCs of normal antral mucosa, whereas GKN2 expression 
was reduced in H. pylori–infected tissues and absent in the majority 
of intestinal metaplasia and GC tissues (Figure 1B).
In mice, GKN2 protein was also stomach specific (Figure 1C), 
and, as previously shown in humans (15), it localized to SMCs of the 
gastric corpus and antrum (Figure 1D). We assessed Gkn2 mRNA 
expression levels in mouse H. pylori infection, transgenic, and 
knockout models, which collectively reproduce H. pylori inflam-
matory, premalignant, and tumorigenic stages of human GC. 
Downloaded from http://www.jci.org on January 19, 2017.   https://doi.org/10.1172/JCI82655
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
1 3 8 5jci.org   Volume 126   Number 4   April 2016
remained significantly elevated in 30-week-old Gkn2–/– mice (Fig-
ure 3C). Overall corpus mucosal thickness in Gkn2–/– mice was not 
significantly different than that of age-matched WT mice (Figure 
3D). Nonetheless, corpus mucosal defects, and lesion areas in 
particular, were associated with an increased epithelial prolifera-
tion rate in 6- and 12-week-old but not 30-week-old Gkn2–/– mice 
(Figure 3E). By contrast, the antral mucosa of Gkn2–/– mice had a 
12- and 30-week-old animals (Figure 3, A and B, and Supplemen-
tal Figure 4). Mucosal defects, including inflammation, glandular 
atrophy, mucus neck cell (MNC) hyperplasia, and replacement of 
periodic acid–Schiff–stained (PAS-stained) neutral mucin with 
Alcian blue–stained acidic mucin in SMC (SMC metaplasia), were 
all significantly increased in the corpus mucosa of 6- and 12-week-
old Gkn2–/– mice, while MNC hyperplasia and SMC metaplasia 
Figure 1. Loss of GKN2 expression in human and mouse GC progression. (A) QRT-PCR analysis of GKN2 mRNA in human GC. Scatter plots show mRNA 
fold changes for H. pylori–infected tissue (HP; n = 16), premalignant tissue adjacent to tumor with intestinal metaplasia (IM; n = 28), and GC tissue (n = 28) 
relative to normal (N; n = 6) gastric epithelial tissues. (B) Representative photomicrographs showing GKN2 immunostaining in human gastric tissues (see 
above). Normal and H. pylori–infected tissue show antral mucosa. Scale bar: 50 μm. Intestinal metaplasia shows corpus mucosa; presence of goblet cells 
is confirmed by AB-PAS staining of an adjacent section. GC shows adenocarcinoma in corpus mucosa. Scale bar: 100 μm (first and second columns and top 
image fourth column); 50 μm (third column and bottom image fourth column). (C) Immunoblots of mouse GKN2 protein. GAPDH verifies protein integrity. 
Two GKN2 bands represent unprocessed precursor (20-kDa) and secreted mature (18-kDa) protein, respectively. Oes, oesophagus; Duo, duodenum; PSI, 
proximal small intestine; MSI, middle small intestine; DSI, distal small intestine. (D) Immunofluorescent localization of mouse GKN2 protein in corpus 
and antrum mucosa. Scale bar: 50 μm (first and third image) and 25 μm (second and fourth image). (E) QRT-PCR analysis of Gkn2 mRNA in H. pylori SS1–
infected WT (C57BL/6) mouse corpus, antrum, or whole stomach at 7 days (7 d), 2 months (2 mo), or 12 months (12 mo). Box plots show median mRNA 
fold change relative to uninfected mice. (F) QRT-PCR analysis of mouse genetic models described in B. (E and F) In box-and-whisker plots, horizontal bars 
indicate the medians, boxes indicate 25th to 75th percentiles, and whiskers indicate 10th and 90th percentiles. P values were determined using a 2-tailed 
Student’s t test: *P < 0.05; ***P < 0.001.
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quantifying expansion of MNC zone and cellular loss within both 
parietal cell and zymogenic cell compartments (Figure 4C). The 
modest reduction in parietal cell number was not associated with 
changes in either stomach acid content (Figure 4D and Supple-
mental Methods) or antral expression of gastrin (Figure 4E), the 
principal endocrine stimulator of acid production. Collectively, 
we believe that these results identify GKN2 as a novel regulator of 
gastric epithelial homeostasis.
Proximal gastric tumorigenesis in GKN2-deficient gp130F/F 
mice. Given the role of GKN2 in maintenance of gastric epithelial 
homeostasis, we asked whether GKN2 genetic loss might potenti-
ate the effects of oncogenic pathways known to induce gastric epi-
normal histological structure, thickness, and epithelial prolifera-
tion count (Figure 3, A, B, D, and E). A detailed study of gastric 
epithelial markers and cellular changes underlying atrophy and 
metaplasia was performed in 12-week-old Gkn2–/– mice (in which 
mucosal lesions and glandular defects are most pronounced). 
Expression of the gastric trefoil factor (Tff1, Tff2) and mucin genes 
(Muc1, Muc5ac, Muc6) was not significantly altered, at least in bulk 
gastric tissue (Figure 4A). However, the SMC metaplasia (show-
ing ectopic Alcian blue staining) was associated with a selective 
loss of MUC5AC, but not TFF1, specifically within lesion areas by 
immunofluorescent staining (Figure 4B). Similarly, MNC hyper-
plasia and glandular atrophy were, respectively, characterized by 
Figure 2. Targeted deletion of the 
mouse Gkn2 locus. (A) Strategy used 
to target the mouse Gkn2 locus. Red 
arrowheads denote primer pairs used 
to amplify WT and targeted alleles 
by PCR. Scale bar: 1 kbp. (B) PCR 
genotyping strategy. WT and targeted 
alleles generate 442-bp and 214-bp 
bands, respectively. Upper and lower 
bands show 500 and 200 bp, respec-
tively. M, molecular weight marker of 
the 100-bp ladder. (C) Immunoblot 
showing GKN2 protein expression 
in WT, Gkn2+/–, and Gkn2–/– gastric 
corpus tissues. Molecular weights 
(kDa) of protein bands are shown. 
Histograms show densitometry of 
protein bands/GAPDH (n = 3 per 
group). P values were determined 
using a 2-tailed Student’s t test: 
***P < 0.001. (D–K) β-Gal reporter 
activity in Gkn2+/– and WT stomachs 
stained with X-gal (bright blue stain). 
(D and E) Macroscopic images of 
X-gal–stained stomachs. Boxed areas 
are shown at higher magnification in 
F and G. Scale bar: 5 mm. (F and G) 
High-magnification images showing 
(F) proximal and (G) distal extents of 
β-gal staining in Gkn2+/– stomachs. 
Scale bar: 500 μm. Original magnifi-
cation, ×2 (inset). (H–K) Histological 
images of (H and I) corpus and (J and 
K) antral β-gal staining in Gkn2+/– 
stomachs (dark blue), with hema-
toxylin counterstain (pale blue). Scale 
bar: 50 μm (H and J); 20 μm (I and K). 
(L–N) Immunofluorescent colocal-
ization of GKN2 and β-gal proteins in 
Gkn2+/– corpus mucosa. Boxed areas 
are shown at higher magnification in 
M and N. Scale bar: 50 μm (L); 20 μm 
(M); 5 μm (N).
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Figure 3. Gkn2–/– mice display impaired basal gastric epithelial differentiation. 
(A) Representative images of the gastric mucosa of 6-, 12-, and 30-week-old 
Gkn2–/– and WT littermate control mice. Boundaries between corpus and antral 
mucosae are delineated with white dashed lines; hypertrophic mucosal lesions 
are shown by black dashed lines. Scale bar: 5 mm. (B) Low-power images 
showing AB-PAS–stained Gkn2–/– hypertrophic lesions compared with nonle-
sion and WT corpus mucosa. Scale bar: 200 μm. High-power images of corpus 
and antrum mucosa in 12-week-old Gkn2–/– and WT mice. Scale bar: 50 μm. (C) 
Summary of semiquantitative histopathology scores for corpus inflammation 
(inflamm), atrophy, MNC hyperplasia (MNC hyp), and SMC metaplasia (SMC 
met) in 6-, 12-, and 30-week-old WT and Gkn2–/– mice (group sizes as stated in 
D). (D) Morphometric analysis of corpus and antral mucosal thickness in 6-, 12-, 
and 30-week-old Gkn2–/– (n = 11, n = 9, n = 7) and WT mice (n = 7, n = 9, n = 8). 
Histograms show mean mucosal thickness as histological cross-sectional area/
mm2 per mm length of muscularis mucosae. (E) Ki-67 labeling of proliferating 
cells in corpus mucosa of 6-, 12-, and 30-week-old WT and Gkn2–/– mice and 
antral mucosa of 12-week-old WT and Gkn2–/– mice (n = 6 per group). Represen-
tative images of 12-week-old WT and Gkn2–/– corpus and Gkn2–/– lesion mucosa 
are shown. Scale bar: 100 μm. Error bars represent mean ± SEM. P values were 
determined using a 2-tailed Student’s t test: *P < 0.05; **P < 0.01; ***P < 0.001.
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thelial tumors in mice. The IL-11/gp130/STAT3 axis is a key driver 
of GC pathogenesis (15, 16). Mice carrying a knockin mutation at 
the gp130 cytokine coreceptor locus (gp130F/F) show STAT3 hyper-
activation and spontaneous tumorigenesis in the antrum, which 
progresses to encompass the entire secretory mucosa. In the antral 
stomach, gp130/STAT3 activation is dependent on the cytokine 
IL-11 (21–23), and the knockin mutant progresses through chronic 
inflammation, metaplasia, and dysplasia to carcinoma in situ, 
phenocopying all but the metastatic stage of human intestinal-
type GC development (16). In contrast to gp130F/F single mutants, 
which mainly show antral tumors, Gkn2–/– gp130F/F compound 
mutants additionally showed extensive focal tumorigenesis of the 
corpus and squamous epithelium overlying the limiting ridge of 
the corpus/forestomach junction at 12 weeks of age (Figure 5A). 
This phenotype was supported quantitatively by an increase in the 
number of corpus tumor foci (Figure 5B) and an increased macro-
scopic corpus tumor area in Gkn2–/– gp130F/F mice (Figure 5C). His-
tological analysis of the tumors revealed a poorly differentiated 
and hyperplastic epithelium (Figure 5, D and E), contributing to 
a significant increase in corpus mucosal thickness overall (Figure 
5F). In contrast, the antral tumor load and mucosal thickness in 
Gkn2–/– gp130F/F mice were not significantly different than those of 
gp130F/F single mutants (Figure 5, A, C, and F). To further charac-
terize the corpus tumor lineage, we examined the β-gal reporter 
expression profile of Gkn2–/– gp130F/F stomach tissues by staining 
with X-gal. Strikingly, while adjacent normal mucosa retained 
strong reporter expression, corpus (and antral) tumors were com-
prised predominantly by unstained cells (Figure 6, A–E). Consis-
tent with the absence of reporter expression (which marks the 
SMC lineage), the tumors also lacked MUC5AC staining, although 
TFF1 expression was retained, while both proteins were abun-
dantly expressed in adjacent nontumoral mucosa (Figure 6, F and 
Figure 4. Cellular and molecular analysis of gastric epithelial differentiation in Gkn2–/– mice. (A) Expression of gastric trefoil factor and mucin genes 
in 12-week-old Gkn2–/– (n = 11) and WT (n = 8) corpus by QRT-PCR. (B) Characterization of SMC differentiation in 12-week-old WT and Gkn2–/– corpus and 
Gkn2–/– lesion mucosa by AB-PAS staining (top row) and immunofluorescent staining for MUC5AC and TFF1 proteins (bottom row). Scale bar: 20 μm. (C) 
Immunofluorescent quantitation of MNCs (MNC, GSII); parietal cells (PC, HK ATPase-β); and zymogenic cells (ZC, pepsinogen II) in 12-week-old WT and 
Gkn2–/– corpus mucosa (n = 6 per group). Scale bar: 20 μm. (D) Gastric acidity determined by pH measurement of stomach contents in Gkn2–/– (n = 11) and 
WT (n = 8) mice. (E) QRT-PCR analysis of gastrin mRNA expression in antral stomachs of Gkn2–/– (n = 11) and WT (n = 8) mice. Error bars represent mean ± 
SEM. P values were determined using a 2-tailed Student’s t test: *P < 0.05; **P < 0.01; ***P < 0.001.
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H). We found no evidence of mucus metaplasia within the tumor 
masses, as shown by a lack of TFF2/Griffonia simplicifolia lectin 
II (TFF2/GSII) staining, although clusters of TFF2/GSII-positive 
cells were seen at the tumor margins and in adjacent nontumoral 
mucosa (Figure 6, G and I). Similarly, none of the Gkn2–/– gp130F/F 
tumors showed evidence of true intestinal metaplasia, as evi-
denced by absence of CDX2 expression (Figure 6, I and J).
Absence of synergistic phenotypes in compound mutant Gkn2–/– Tff1–/– 
mice. We examined the effect of GKN2 genetic deficiency in the Tff1–/– 
gastric tumor model. Our rationale was 3-fold: (a) Tff1–/– mice show 
gastric epithelial hyperplasia progressing to antral tumorigenesis at 
3 to 6 months of age (17); (b) TFF1 shows closely overlapping cellu-
lar expression with GKN2 (13), raising the possibility of potentiation 
of individual pathological outcomes; (c) GKN2 and TFF1 have been 
reported to form heterodimers (14), suggesting cooperative func-
tion. Compound mutant Gkn2–/– Tff1–/– mice showed no differences 
in tumor incidence, mucosal thickness, or temporal progression at 
12 weeks of age compared with single mutant Tff1–/– or Gkn2–/– mice 
(Supplemental Figure 5). Therefore, GKN2 deficiency does not sig-
nificantly influence tumorigenesis in Tff1–/– mice and vice versa, 
Figure 5. Proximal stomach tumorigenesis in Gkn2–/– gp130F/F compound mutant mice. (A) Representative images of corpus and antral tumor phenotypes 
in 12-week-old Gkn2–/– gp130F/F compound mutants (n = 13) compared with gp130F/F (n = 5) and Gkn2–/– single mutants (n = 12) and WT (n = 6) littermate 
control mice. White dashed lines delineate boundaries between corpus and antrum; tumor areas are shown by red (corpus) or black (antral) dashed lines. 
Scale bar: 5 mm. (B and C) Morphometric analysis of tumor burden in Gkn2–/– gp130F/F compound mutants. (B) Corpus tumor incidence expressed as the 
number of tumor foci within gastric corpus. (C) Macroscopic area of corpus and antral tumors in mm2. (D) Low-power images showing differential tumor 
histology (AB-PAS staining) in Gkn2–/– gp130F/F compound mutant and gp130F/F single mutant stomachs. Scale bar: 500 μm. (E) High-power histological 
images (original magnification, ×100 [top row]; ×400 [bottom row]) of corpus mucosal defects in Gkn2–/– gp130F/F mice stained with AB-PAS. Scale bar: 50 
μm. (F) Morphometric analysis of corpus and antral mucosal thickness in Gkn2–/– gp130F/F compound mutants. Error bars represent mean ± SEM. P values 
were determined using a 2-tailed Student’s t test: *P < 0.05.
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sion of zymogenic cell and parietal cell lineage mark-
ers Mist1 and HKβ, respectively (Figure 7D). Infected 
Gkn2–/– mice also had lower H. pylori colonization lev-
els (Figure 7E), which were inversely correlated with 
gastritis severity (Figure 7F), suggesting preferential 
immune-mediated reduction in bacterial load and/
or loss of niche due to mucosal damage. Collectively, 
these results demonstrate a previously undescribed 
antiinflammatory function of GKN2, which sup-
presses H. pylori–related inflammation and premalig-
nant disease progression in the stomach.
Hyperactivated Th1 immunity in H. pylori–infected 
Gkn2–/– mice. H. pylori–related gastritis is typically 
driven by a dual T helper cell type 1 (Th1) and Th17 
immune response, while Th1 and Th17 pathways are 
modulated by Th2 and Treg cytokine responses. To 
better understand mechanisms underlying augmented inflam-
matory responses in Gkn2–/– mice, we first measured levels of 
anti–H. pylori IgG antibody subclasses. Relative to that in WT mice, 
infected Gkn2–/– mice presented with an antibody response that 
was skewed toward the IgG2c subclass, which is consistent with an 
increased Th1 immune response (Figure 8A). To consolidate this 
finding, we quantified by QRT-PCR expression levels of cytokines 
and transcription factors that are markers for Th1, Th2, Th17, and 
Tregs as well as markers of associated M1- and M2-type macro-
phage responses. Infected Gkn2–/– mice expressed higher mRNA 
levels of proinflammatory Th1 markers Ifng and Tbet (Figure 8B) as 
well as the M1-associated Il1b, Il6, Il11, and Cxcl2 (Figure 8C) and 
antimicrobial peptide genes Dmbt1 and Reg3g (Figure 8D) com-
pared with infected WT or uninfected controls. Il10 and Foxp3 were 
also preferentially induced, consistent with an attempt by Foxp3+ 
Tregs to limit inflammatory damage ensuing from the elevated Th1 
response (Figure 8E). By contrast, neither Th2 (Figure 8F) nor Th17 
lineage markers (Figure 8G) showed broad expression differences 
in infected Gkn2–/– mice compared with infected WT mice. There-
fore, neither Th2 nor Th17 immunity was differentially activated 
in infected Gkn2–/– mice. However, M2-related arginase 1 (Arg1), 
a key suppressor of T cell responses (27), showed significantly 
decreased expression in infected Gkn2–/– mice (Figure 8F), again 
arguing that GKN2-TFF1 heterodimers are not, at least in mice, 
required for individual component suppressive function.
H. pylori–infected Gkn2–/– mice show accelerated progression to 
atrophic gastritis and metaplasia. Having shown that GKN2 restrains 
the progression of cytokine-driven proximal gastric tumorigene-
sis, we investigated Gkn2 genetic loss in the context of H. pylori–
dependent gastritis, a key premalignant lesion of GC (24). Three 
independent cohorts of 6- to 8-week-old Gkn2–/– and WT control 
mice were orally infected with H. pylori SS1 (25), sacrificed at 2 
MPI (Figure 7A), and examined for gastric histopathology. Infected 
Gkn2–/– mice showed increased severity of atrophic gastritis and 
pervasive frequent Alcian blue–positive mucus metaplasia (con-
sistent with spasmolytic polypeptide expressing metaplasia; ref. 
26). By contrast, infected WT mice showed relatively mild inflam-
matory pathology, infrequent atrophy, and metaplasia (Figure 7B), 
consistent with the known temporal progression of this infection in 
C57BL/6 mice (25). Accordingly, infected Gkn2–/– mice had higher 
scores of corpus polymorphonuclear and mononuclear infiltrate, 
glandular atrophy, and mucus metaplasia, while antral inflamma-
tory scores, though increased from uninfected levels, were similar 
in Gkn2–/– and WT mice (Figure 7C). Consistent with the severity 
of atrophy and metaplasia, infected Gkn2–/– mice showed increased 
corpus expression of mucin 6 (Muc6) mRNA and decreased expres-
Figure 6. Analysis of gastric and intestinal differentiation 
in Gkn2–/– gp130F/F proximal stomach tumors. (A–C) β-Gal 
reporter gene expression in Gkn2–/– gp130F/F gastric corpus 
tumors. Representative Gkn2–/– gp130F/F stomach shown (A) 
before and (B) after X-gal staining. Tumor areas are shown 
by red (corpus) or (A) black or (B) green (antral) dashed 
lines. Scale bar: 5 mm. (C) Lateral images of X-gal–stained 
and sagittally bisected Gkn2–/– gp130F/F stomach tissues. 
Red (corpus) and green (antral) arrows indicate tumor 
masses. Scale bar: 3 mm. (D and E) Histological images of 
X-gal–stained Gkn2–/– gp130F/F tumors in (D) corpus and (E) 
antrum. Scale bar: 100 μm. (F and G) Low-power image of (F) 
MUC5AC and TFF1 double immunofluorescent staining and 
(G) TFF2, GSII, and CDX2 triple staining in corpus tumors and 
adjacent nontumoral mucosa of Gkn2–/– gp130F/F mice. Scale 
bar: 200 μm. (H and I) High-power images showing staining 
patterns at tumor margin for (H) MUC5AC and TFF1 and (I) 
TFF2, GSII, and CDX2. Scale bar: 100 μm. (J) CDX2 staining in 
colonic epithelium (positive control). Scale bar: 50 μm.
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Figure 6). These results indicate that GKN2 restrains gastric immu-
nopathology by modulating Th1, but not Th17, immunity.
Inflammatory phenotype of Gkn2–/– mice is unrelated to chemo-
kine production by GECs. Chemokine secretion by epithelial cells 
consistent with the proinflammatory phenotype of this model. 
Given that effects of GKN2 deficiency are predominantly on cor-
pus pathology, none of the above immune markers were differen-
tially expressed in the antra of infected Gkn2–/– mice (Supplemental 
Figure 7. Accelerated progression to atrophic gastritis and mucus metaplasia in Gkn2–/– mice after 2-month H. pylori infection. (A) Strategy used for 2-month 
H. pylori SS1 infections. (B) Macroscopic and histological images of Gkn2–/– and WT littermate stomachs infected for 2 months and uninfected control stomachs. 
White dashed lines delineate corpus/antrum boundaries. Arrows show the region of corpus hypertrophy in the infected Gkn2–/– stomach macroscopic photo. 
Scale bar: 5 mm (macroscopic images); 50 μm (histological images). (C) Semiquantitative histological assessment of gastric histopathology: inflammatory 
infiltrate (polymorphonuclear cells [PMN]; mononuclear cells [MN]), atrophy (degree of parietal/zymogenic cell loss), and mucus metaplasia (Met). Histograms 
show mean pathology scores for each parameter (range 0–4). (D) QRT-PCR analysis of metaplasia (Muc6) and glandular atrophy–related (Mist1 and HKβ) genes 
in Gkn2–/– mice after 2 months of H. pylori infection. Histograms show mean mRNA fold change relative to WT uninfected mice. (E) H. pylori SS1 colonization 
levels in stomachs after 2 months of infection, as assessed by Q-PCR (Supplemental Methods). Histograms show mean colonization level (104 H. pylori genomes 
per 105 Gapdh copies). (F) Linear regression analysis of corpus inflammation score and colonization level. The correlation coefficient (r2) value is shown. Error 
bars represent mean ± SEM. P values were determined using a 2-tailed Student’s t test (C) or 2-tailed Mann Whitney U test (D and E). Statistical significance 
compared with WT uninfected control mice: #P < 0.05. Statistical significance between treatment groups: *P < 0.05; **P < 0.01; ***P < 0.001.
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Gkn2–/– cultures, respectively (Supplemental Figure 7B). Unstim-
ulated Gkn2–/– and WT GECs showed no differences in secretion 
of 23 chemokines/cytokines at baseline, and, while GECs coincu-
bated with live H. pylori for 24 hours showed increased production 
of CCL3, CCL4, IL-1α, IL-1β, TNF-α, IL-6, and IL-10, these out-
puts were similar in Gkn2–/– and WT cultures (Supplemental Figure 
7C). Therefore, the proinflammatory phenotype of Gkn2–/– mice is 
unrelated to chemokine secretion by GECs.
Gkn2–/– mice show heightened mucosal innate immunity and 
impaired myeloid-derived suppressor cell responses. To elucidate 
mechanisms initiating Th1 inflammatory responses in Gkn2–/– 
mice, we examined the early phase of immune activation at 7 days 
is a key mechanism driving myeloid cell recruitment to the gas-
tric mucosa and plays a pivotal role in triggering the host innate 
response to H. pylori infection (28). We hypothesized that GKN2 
genetic loss might enhance chemokine release from GECs. To 
address this, we compared the chemokine/cytokine secretory 
responses of primary GECs derived from Gkn2–/– and WT mice 
in a H. pylori SS1 coculture assay (Supplemental Figure 7A). Pri-
mary GEC cultures were prepared using established methods 
(29). Purity of the epithelial cultures was confirmed by staining for 
pan-cytokeratin and absence of CD45 (immunocytes) and smooth 
muscle actin (mesenchymal cells). The presence of (GKN2-secret-
ing) SMCs was verified by staining for GKN2 or β-gal in WT and 
Figure 8. Differential expression of cytokines and immune transcription factors in Gkn2–/– mice after 2-month H. pylori infection. (A) ELISA detection of 
serum IgG antibody responses in Gkn2–/– mice infected for 2 months. Box plots show median (horizontal bars), interquartile range (boxes) and 10th/90th 
percentile (error bars) titers of individual anti–H. pylori IgG2c (Th1) and IgG1 (Th2) and combined IgG2c/IgG1 ratio. (B–F) QRT-PCR cytokine/chemokine/
transcription factor expression profiles of Gkn2–/– mice infected for 2 months. (B) Th1 markers (Ifng, Tbet); (C) M1 markers (Il1b, Cxcl2, Il6, Il11); (D) antimi-
crobial lectins (Reg3g, Dmbt1); (E) Treg markers (Il10, Foxp3); (F) Th2/M2 markers (Arg1, Il4, Il5, Fizz1, Ym1, Il1rn); and (G) Th17 markers (Rorc, Il17a, Il17f). 
Histograms show mean mRNA fold change relative to WT uninfected mice. Error bars represent mean ± SEM. P values were determined using a 2-tailed 
Student’s t test: *P < 0.05; **P < 0.01.
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decreased bacterial density occurs prior to the establishment of 
overt gastritis. To exclude impaired bacterial adhesion to GECs as 
a mechanism of decreased colonization, we quantified the adhe-
sion of live H. pylori to MKN28 GECs transfected with inducible 
GKN2 expression constructs (Supplemental Methods) and found 
after infection with H. pylori (ref. 30 and Figure 9A). H. pylori col-
onization levels were again reduced in Gkn2–/– mice infected for 
7 days (Figure 9B and Supplemental Figure 8) in the absence of 
evident inflammation. Therefore, the Gkn2–/– gastric niche appears 
less receptive, even to acute H. pylori colonization, suggesting that 
Figure 9. Analysis of gastric mucosal cytokines and immune cell populations in Gkn2–/– mice after 7-day H. pylori infection. (A) Strategy used for 7-day 
H. pylori SS1 infections. (B) Q-PCR analysis of H. pylori SS1 colonization levels in 7-day infected Gkn2–/– and WT stomachs (n = 7 per group). Histograms 
show mean colonization level (104 H. pylori genomes per 105 Gapdh copies). (C–E) Luminex array analysis of cytokine/chemokine protein levels in corpus 
homogenates from 7-day infected Gkn2–/– and WT (n = 7 per group) and uninfected control mice (n = 8 per group): (C) TNF-α, IL-1α, IL-6, CXCL1, and CCL4; 
(D) IL-10; and (E) IFN-γ. Histograms show mean normalized levels (pg cytokine/100 mg total protein). (F–H) Flow cytometry analysis of myeloid/lymphoid 
cells in stomachs of 7-day infected Gkn2–/– mice and uninfected controls (n = 5 per group): (F) macrophage (CD11b+F4/80+Gr1–) and DC (CD11c+); (G) Treg 
(CD4+CD25+Foxp3+); and (H) total MDSC, monocytic MDSC (Mo-MDSC) (CD11b+Ly6ChiLy6G–CD49d+), and granulocytic MDSC (Gr-MDSC) (CD11b+Ly6Clo 
Ly6G+CD49d–) subsets. Histograms show mean cellular prevalence (percentage of total gastric leukocytes). (I) QRT-PCR expression profiles of MDSC differ-
entiation (Ccr2, IL4ra) and activation (S100a8, S100a9, Arg1, Arg2, Tgfb1, Tgfb2) genes in 7-day infected Gkn2–/– mice. Error bars represent mean ± SEM.  
P values were determined using a 2-tailed Student’s t test or 2-tailed Mann Whitney U test (I, only). Statistical significance compared with WT uninfected 
control mice: #P < 0.05; ##P < 0.01. Statistical significance between treatment groups: *P < 0.05; **P < 0.01; ***P < 0.001.
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proinflammatory cytokines), which rapidly breaks down upon 
H. pylori challenge, allowing enhanced priming of Th1 immunity.
We next investigated whether the altered gastric cytokine 
profile of Gkn2–/– mice was due to effects in epithelial or immune 
cells. To address this question, we isolated gastric epithelial and 
immune cell populations from stomachs of uninfected WT and 
Gkn2–/– mice by FACS (Supplemental Methods) and analyzed their 
cytokine expression by QRT-PCR. The results showed that Il1a, 
Il6, Tnfa, and Ccl4 mRNA were specifically localized within gas-
tric immune cells, not epithelial cells (Supplemental Figure 11). 
To identify specific immune cell subsets, we next assessed gastric 
mucosal myeloid and lymphoid populations by flow cytometry (full 
that H. pylori adhesion was not regulated by GKN2 (Supplemen-
tal Figure 9). To characterize immune profiles associated with this 
host response, we assessed cytokine levels in stomachs of unin-
fected mice and mice infected for 7 days by luminex array analysis 
(Supplemental Methods). TNF-α, IL-6, IL-1α, CXCL1, and CCL4 
were elevated specifically in corpus (but not antrum) tissues of 
uninfected Gkn2–/– mice, showing no additional increase at 7 days 
after H. pylori infection (Figure 9C and Supplemental Figure 10). 
Gkn2–/– mice also had basally increased IL-10, which decreased 
to WT levels at 7 days after infection (Figure 9D), concomitant 
with increased production of IFN-γ (Figure 9E). These results are 
consistent with basal immunoregulation (to counteract elevated 
Figure 10. Generation of human GKN2/GKN1-overexpressing BAC transgenic mice. (A) Structure of the 152-kb human BAC transgene showing relative 
locations of the GKN1 and GKN2 genes (white boxes), with their transcriptional orientation shown in expanded images. The nonexpressed GKN3 pseu-
dogene is shown as a solid black box. (B) QRT-PCR analysis of human GKN1 (hGKN1) and GKN2 mRNA expression in stomach (Stom) and spleen (Spl) 
tissues from line 5 and line 9 BACTg and WT littermate control mice (n = 3 per group). (C) Immunoblot analysis of human GKN2 protein in gastric corpus 
(Crp), antrum (Ant), and spleen (Spl) tissues of line 5 and line 9 BACTg and WT littermate control mice. Protein molecular weights (kDa) are shown. (D) 
Immunofluorescent localization of human GKN2 protein in gastric corpus and antrum of line 5 BACTg and WT littermate control mice. Sections were 
counterstained with DAPI. Scale bar: 50 μm. (E) Corpus and antrum mucosal histopathology in line 5 and line 9 BACTg mice. Scale bar: 5 mm (macropho-
tographs); 50 μm (histological images).
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infected Gkn2–/– mice could be due to APC-mediated skewing away 
from a tolerogenic Treg response toward a proinflammatory Th1 
response. However, in fact, uninfected Gkn2–/– mice had a higher 
gastric mucosal prevalence of CD4+CD25+Foxp3+ Tregs, which 
was sustained in mice infected for 7 days (Figure 9G). Therefore, 
the proinflammatory phenotype of Gkn2–/– mice is independent of 
gastric Treg responses.
Myeloid-derived suppressor cells (MDSCs) are a mixed popu-
lation of immature myeloid lineages, including granulocyte, mac-
rophage, and DC progenitors (27). MDSCs dampen proinflamma-
gating strategy shown in Supplemental Figure 12). An increased 
prevalence of CD11b+F4/80+Gr1– macrophages and CD11c+ DCs 
was found in Gkn2–/– mice compared with that in WT mice (Figure 
9F and Supplemental Figure 13), suggesting that tissue-resident 
APCs might play a role in shaping the temporal onset, magnitude, 
and specific polarity of inflammatory responses in Gkn2–/– mice.
Induction of immune tolerance to H. pylori via recruitment of 
CD4+CD25+Foxp3+ Tregs occurs during the initial phases of infec-
tion, leading to delayed onset of inflammatory pathology (31). We 
hypothesized that accelerated onset and severity of gastritis in 
Figure 11. Reduced antral tumor growth in human GKN2/GKN1-overexpressing BACTg gp130F/F mice. (A) Representative images of stomachs from line 5 
and line 9 BACTg gp130F/F compound transgenic mice and gp130F/F single mutant littermate controls are shown; black dashed lines delineate tumor margins. 
Scale bar: 5 mm. (B) Weight of fresh stomach in grams. (C) Macroscopic area of antral tumors in mm2. (D) Weight of fresh spleen in grams in line 5 and 
line 9 BACTg gp130F/F compound transgenic (n = 16/n = 16) mice, gp130F/F single mutants (n = 12/n = 12), BACTg mice (n = 7/n = 14), and WT (n = 5/n = 12) 
littermate controls. (E) Tumor histology in representative BACTg gp130F/F compound transgenic mice and gp130F/F single mutants. Scale bar: 200 μm. (F) 
Morphometric analysis of antral mucosal thickness. Histograms show the mean mucosal thickness as the histological cross section area in mm2 per unit 
length of muscularis mucosae. Biological replicates per group as stated for D. Error bars represent mean ± SEM. P values were determined using a 1-tailed 
Mann Whitney U test (B and D) or 1-tailed Student’s t test (C and F): *P < 0.05; **P < 0.01.
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Antral tumor growth was significantly reduced in 12-week-old 
BACTg gp130F/F compound mutants, as assessed by reduced total 
stomach weight (Figure 11B) and macroscopic area of the tumor 
mass (Figure 11C) compared with gp130F/F single mutant control 
mice. Interestingly, the splenomegaly that is typically observed 
in gp130F/F mice was significantly reduced in BACTg gp130F/F com-
pound mutants, consistent with an effect of the reduced tumor 
load on systemic immunity (Figure 11D). Reduced tumor mass in 
BACTg gp130F/F mice was particularly evident in histological analy-
sis, with both compound transgenic lines showing decreased over-
all thickness of the antral mucosa compared with gp130F/F single 
mutants (Figure 11, E and F). These results establish restoration 
of human GKNs as a potential therapeutic approach to suppress 
gastric tumor growth.
Discussion
In a knockout mouse model, we have demonstrated an unexpected 
antiinflammatory function for the gastric mucus cell–associated 
protein, GKN2 (8). We have presented in vivo evidence that GKN2 
loss, in the context of chronic inflammation induced by H. pylori 
infection, or cytokine-directed tumorigenesis plays a causal role in 
GC progression. Using a transgenic approach, we have additionally 
shown that dual overexpression of GKN2 and GKN1 can signifi-
cantly restrain gastric tumor growth in vivo. This study provides the 
first major in vivo functional analysis of any of the GKN family pro-
teins to our knowledge. The findings highlight the potential clinical 
application of these epithelial-derived secreted factors to subdue 
gastric inflammation and consequent malignant progression.
GKN2 was first linked to GC more than a decade ago, fol-
lowing its initial discovery as a protein downregulated in gastric 
adenocarcinomas (8, 34). Subsequent studies have shown GKN2 
expression loss to be one of the most frequent alterations in both 
adenocarcinomas (6, 13, 35, 36) and gastric tumor cell lines (6, 35), 
while, conversely, GKN2 overexpression inhibits proliferation, 
migration, and invasion of cell lines and tumor xenografts (8, 34, 
35). GKN2 therefore appeared to satisfy several of the requisite cri-
teria of a TSG, ostensibly being expressed in normal cell lineages 
(GECs) giving rise to cancer, imposing restraint on proliferation, 
and showing absence from tumor cells. Nevertheless, for a gen-
uine TSG function to be formally ascribed, a causal link between 
expression loss/protein inactivation in a tumor progenitor cell and 
subsequent oncogenic transformation of derived lineages must be 
unequivocally established. We instead found that GKN2 loss, in 
isolation from oncogenic or inflammatory drivers, is insufficient 
for cell-autonomous transformation, since Gkn2–/– mice lacked 
spontaneous tumor growth or significant epithelial hyperplasia, 
even at advanced (>30 weeks) age.
Previous studies have focused exclusively on a putative and, 
now debatable, “classical TSG” function for GKN2 (reviewed in 
ref. 6) but have not considered alternative roles. Our findings here 
reveal previously undescribed antiinflammatory and mucosal 
homeostatic activities as the principal in vivo functions of GKN2. 
Effects of GKN2 deficiency were relatively mild at baseline, char-
acterized mainly by impaired gastric epithelial differentiation. 
However, loss of GKN2 was found to profoundly exacerbate gas-
tric immunopathology when placed in context of an inflamma-
tory challenge, namely H. pylori infection or genetically induced 
tory T cell responses (including Th1 immunity against H. pylori; 
ref. 32) via production of arginase, inducible nitric oxide synthase, 
and immunosuppressive cytokines (27). In mice, monocytic and 
granulocytic MDSC subsets can be discriminated by CD11b+ 
Ly6ChiLy6G–CD49d+ and CD11b+Ly6CloLy6G+CD49d– surface 
phenotypes, respectively (33). We assessed MDSCs in stomachs of 
uninfected Gkn2–/– mice and Gkn2–/– mice infected for 7 days by flow 
cytometry. The total number of MDSCs was significantly reduced 
in uninfected Gkn2–/– mice, due to specific deficiency in the mono-
cytic MDSC subset (Figure 9H and Supplemental Figure 13), an 
effect that was sustained after H. pylori infection. These data were 
corroborated by reduced gastric mRNA expression of the MDSC 
markers Ccr2 and IL4ra (33) in uninfected Gkn2–/– stomachs com-
pared with WT stomachs (Figure 9I). We surmised that enhanced 
inflammatory responses in Gkn2–/– mice could therefore be linked to 
compromised MDSC responses. Consistent with this expectation, 
markers of MDSC activation and expansion, S100a8 and S100a9, 
were upregulated in WT stomachs infected for 7 days but conversely 
were downregulated in infected Gkn2–/– stomachs. Similarly, argin-
ase genes (Arg1 and Arg2) and immunosuppressive cytokines (Tgfb1 
and Tgfb2) were upregulated (or trended toward increased expres-
sion) in WT stomachs infected for 7 days but were either unchanged 
or downregulated in infected Gkn2–/– stomachs (Figure 9I). These 
data suggest that impaired activation of MDSCs and breakdown 
of IL-10–mediated immunoregulation, combined with recipro-
cal enrichment of APCs (macrophages and DCs), contribute to an 
enhanced Th1 response in H. pylori–infected Gkn2–/– mice.
Overexpression of human GKNs restrains gastric tumor growth in 
vivo. Having established that GKN2 loss can promote GC patho-
genesis, we asked whether restoration of GKN2 expression in vivo 
might suppress disease progression. We reasoned that because 
GKN2 is normally expressed at unusually high levels, in a discrete 
and lineage-restricted manner, clinically meaningful outcomes 
might only be achieved if overexpression to restore GKN2 is driven 
at a sufficiently high level and in the appropriate cellular context, 
i.e., specifically in gastric SMCs. We addressed this problem by 
engineering a large (152-kb) BAC transgene encompassing the 
entire human GKN2 and GKN1 genomic region (Figure 10A). This 
strategy, resulting in combined human GKN2 and GKN1 expres-
sion, was necessary to include sufficient flanking sequence (i.e., 
containing all native regulatory elements) to drive an amplitude 
and lineage specificity of overexpression that cannot be accom-
plished using conventional transgenic approaches. Two BAC 
transgenic (BACTg) founder lines with a high level of transgene 
expression, line 5 and line 9, were identified by QRT-PCR and 
immunoblotting studies (Figure 10, B and C). As surmised above, 
the BAC transgene directed human GKN2 (and GKN1) mRNA/
protein expression exclusively to the stomach, with absolute spec-
ificity to gastric SMCs (Figure 10D), thus replicating their endoge-
nous expression. BACTg mice displayed normal gastric mucosal 
histology at 12 weeks of age (Figure 10E), showing that overex-
pression of human GKNs does not alter basal gastric homeostasis. 
To investigate the impact of human GKN overexpression on gas-
tric tumorigenesis, we generated two independent BACTg gp130F/F 
compound mutant strains using BACTg mice from line 5 and line 
9, respectively. Representative stomachs collected from both 
BACTg gp130F/F compound mutant strains are shown in Figure 11A. 
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Ifng–/– mice do not develop gastritis (40), while transgenic overex-
pression of IFN-γ is sufficient for induction of atrophic gastritis 
and metaplasia independently of H. pylori infection (41). Thus, 
elevated IFN-γ is likely central to the premalignant phenotype of 
infected Gkn2–/– mice, especially given that Th17 cytokines were 
not differentially induced. The localization of immunopatholog-
ical responses in the corpus in Gkn2–/– mice is highly reminiscent 
of that associated with corpus-predominant gastritis in humans, 
which is similarly characterized by a Th1-skewed response and 
carries high risk of progression to advanced metaplasia, dyspla-
sia, and intraepithelial tumor growth (42). Our data indicate that, 
even partial GKN2 expression loss, particularly in the context of 
Th1-type cytokine gene polymorphisms (43, 44), may strongly 
influence premalignant outcomes in H. pylori–infected individuals 
with corpus-predominant disease.
In short-term (7-day) infection studies, we found that Th1 
immune bias in Gkn2–/– mice may relate to heightened basal innate 
immunity. Gkn2–/– mice showed mucosal enrichment of proin-
flammatory cytokines and increased prevalence of macrophages 
and DCs, which likely prime an exaggerated IFN-γ response upon 
exposure to H. pylori. Both macrophages and DCs, via professional 
antigen-presenting capabilities, are known to initiate adaptive 
responses against H. pylori, in part by secretion of Th1-polarizing 
(and Th17-polarizing) cytokines, IL-12 (and IL-23), respectively 
(45–48). Basally increased IL-10 (and mucosal Tregs) may also 
explain why Gkn2–/– mice resist pathological progression when 
unchallenged. Another factor contributing to the Gkn2–/– phenotype 
may have been MDSCs, which inhibit T cell proliferation in mouse 
models of GC (19) and suppress effector T cells, which drive gas-
tric immunopathology (49, 50). Impaired gastric MDSC responses 
to H. pylori infection may have contributed to the accelerated T 
cell–driven immunopathology in this model. Although MDSCs 
have been widely described to exacerbate cancer progression via 
suppression of CD8+ T cell–mediated antitumor immunity and pro-
motion of angiogenesis (27), recent work suggests that MDSCs, via 
secretion of IL-10, may also participate in the resolution of bacterial 
inflammation (51). Proinflammatory roles of MDSCs in established 
H. pylori infections have been proposed by others (32, 52). Our data 
argue that immunosuppressive functions of MDSCs are required 
to dampen early gastric responses to H. pylori infection. Given that 
gastric SMCs are the sole physiological source of GKN2 (see Figure 
1D; Figure 2, D–N; refs. 6, 9, and literature cited therein), it is rea-
sonable to argue that altered gastric mucosal immune profiles of 
Gkn2–/– mice relate to paracrine deficiency of secreted GKN2 pro-
tein. Understanding the molecular basis of GKN2 paracrine activ-
ity toward specific myeloid cell subsets, including MDSCs, will be a 
priority if its clinical potential is to be realized.
Functional effects of GKN2 loss have been firmly established 
here, yet a key question not addressed by this study is what trig-
gers GKN2 loss (or decreased expression) in the first place? Nei-
ther cytogenetic aberrations encompassing chromosome 2p13.3 
(where the GKNs are located) nor GKN2 somatic mutations have 
been reported in GC (53–55), while epigenetic silencing of GKN2 
applies to only a minority of gastric tumors (55). Together, these 
studies argue that mechanisms other than cytogenetic or epi-
genetic anomalies are mainly responsible for GKN2 expression 
loss. Our findings of decreased Gkn2 mRNA in Il1b and Gm-CSf 
hyperactivation of oncogenic gp130/STAT3 signaling. Interest-
ingly, Gkn2+/– heterozygous mice (not described in Results sec-
tion), though phenotypically normal at baseline (Supplemental 
Figure 14), showed increased susceptibility to H. pylori–dependent 
immunopathology, which is of intermediate severity to that dis-
played by WT and Gkn2–/– mice (Supplemental Figure 15). These 
data argue that even partial loss of GKN2, as typically seen from 
the onset of premalignant disease, may be clinically significant.
Genetic loss of GKN2 in gp130F/F mice elicited rapid tum-
origenesis of the corpus mucosa but, interestingly, did not alter 
antral tumor growth. However, GKN2 expression is already sub-
stantially reduced in gp130F/F antral tumors, such that loss of the 
residual expression in Gkn2–/– gp130F/F mice would have had little 
additional impact on tumor growth. As such, these contrasting 
effects of GKN2 deficiency in corpus and antrum likely relate to 
the preexisting gp130F/F antral pathology and should not necessar-
ily be taken as evidence of preferential GKN2 activity in the corpus. 
Indeed, our BAC transgenic studies suggest that GKN2 has similar 
antitumor activity in antral mucosa. Our dual GKN1/GKN2 trans-
genic strategy has not allowed explicit attribution of the tumor 
inhibition to GKN2. However, the clear dosage effects of GKN2 
shown here (Supplemental Figure 15) argue that transgenic excess 
of GKN2 would have likely contributed to the reduced tumor load 
in some manner. It is noteworthy that GKN1 and GKN2 display 
identical expression in normal gastric SMCs and show coordinate 
expression loss in GC (7). As such, our tumor rescue data affirm 
the translational rationale for combined GKN1/GKN2 overexpres-
sion in GC. Additionally, these studies provide functional valida-
tion for earlier clinical associations of higher level GKN1/GKN2 
expression and better outcome in human GC (37).
Strikingly, corpus and antral tumors induced in Gkn2–/– 
gp130F/F mice lacked expression of the Gkn2-lacZ reporter allele, 
yet regions of adjacent nontumoral mucosa retained reporter 
expression. These observations could suggest inactivation of 
GKN2 within a tumor progenitor cell but are equally consistent 
with expansion of tumors from immature epithelial lineages lack-
ing GKN2 expression. Long-lived gastric epithelial progenitor 
cells and bone marrow–derived cells, neither of which express 
GKN2, have been implicated in the origin of GC (37, 38). Evidence 
also exists to support transdifferentiation of mitotically quiescent 
zymogenic cells (zymogenic cell) into a metaplastic lineage that 
ultimately gives rise to GC (39). On the other hand, the current 
literature does not support an origin of GC from short-lived gas-
tric SMCs, the sole GKN2-expressing gastric lineage. We therefore 
propose that GKN2 may not be “inactivated” in a tumor progen-
itor but rather that the epithelial progenitors to GC have never 
expressed GKN2, thereby explaining its absence in gastric tumors. 
Accordingly, GKN2 may instead act non–cell autonomously as an 
antiinflammatory paracrine signal that maintains homeostatic 
epithelial turnover and prevents malignant transformation.
Our finding of accelerated immunopathology in H. pylori–
infected Gkn2–/– mice supports an antiinflammatory role for GKN2. 
Infected Gkn2–/– mice showed enhanced mucosal Th1 responses, 
as evidenced by markedly elevated Ifng and Tbet mRNA, concom-
itant skewing toward the IgG2c subclass in the H. pylori antibody 
humoral response, and reduced H. pylori colonization. IFN-γ is a 
key determinant of H. pylori–related pathology; H. pylori–infected 
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genic mice, BACTg line 5 and BACTg line 9 mice (C57BL/6) were each 
independently crossed with gp130F/F mice (C57BL/6).
Mice. Mouse strains, including the gp130F/F mutant (a gift from Mat-
thias Ernst, Olivia Newton John Cancer Research Institute, Melbourne, 
Australia; ref. 15), HKβ–/– (a gift from Ian van Driel, Bio21 Molecular 
Science and Biotechnology Institute, Melbourne, Australia; ref. 62), 
TgCMV-cre1Cgn transgenic (CMV-CreTg; a gift from Ursula Lichtenberg, 
University of Cologne, Cologne, Germany; ref. 20), Tff1–/– (17), Gkn2–/– 
(generated in-house), and human GKN2/GKN1 BAC transgenic mice 
(generated in-house), were maintained on a C57BL/6 genetic back-
ground. All strains were housed under specific pathogen–free condi-
tions. Gastric tissues from HKβ promoter Gm-CSf transgenic (Gm-CSf Tg) 
mice (BALB/c strain background) (63) were a gift from Ian van Driel. 
Gastric tissues were also obtained from HKβ promoter IL1β transgenic 
(IL1βTg) mice that have been described previously (19). All experiments 
involving the above strains used matched WT littermate controls.
H. pylori infection in mice. Mouse-adapted H. pylori SS1 (vacA+, 
cagPAI dysfunctional; ref. 25) was grown in brain-heart infusion broth 
(Oxoid) containing 5% horse serum (JRH Biosciences) and 0.02% 
amphostat (Invitrogen), under microaerophilic conditions for 24 
hours at 37°C. Mice were infected intragastrically with a single dose 
of 107 H. pylori SS1 CFU suspended in 100 μl brain-heart infusion 
broth as described previously (64). H. pylori colonization levels were 
subsequently quantified by TaqMan quantitative PCR assay on stom-
ach extracts (full details provided in the Supplemental Methods) or by 
CFU assay as described previously (64).
Histopathology. Stomach tissues were collected at necropsy, fixed 
in 4% paraformaldehyde in PBS overnight, and processed for stan-
dard paraffin wax histology. Slides were stained for presence of neu-
tral (gastric-type) and acidic (intestinal-type) mucins with Alcian blue 
PAS (AB-PAS) reagent and scored for pathology on a scale of 0 to 4 
by a blinded observer as described previously (65), with modifications 
(full details, including criteria for individual scores, are provided in the 
Supplemental Methods).
Immunohistochemistry and immunofluorescence. Immunohisto-
chemistry was performed as described previously (9). Bound immu-
nocomplexes were detected using Vectastain ABC reagents (Vec-
tor Laboratories), and staining was visualized by incubation in 3, 
3′-diaminobenzidine tetrahydrochloride reagent (Sigma-Aldrich). 
Immuno fluorescence in cultured cells was performed as described 
previously (9). Primary antibodies and lectins used are as follows: 
rabbit polyclonal anti-mouse GKN2 (R771-B3) and anti-human GKN2 
(R779-B3; custom generated, see Supplemental Methods), each 
diluted 1:500; mouse monoclonal anti-human Ki67 (Abcam) diluted 
1:500; lectin GS-II from Griffonia simplicifolia (EY Labs) used at 10 μg/
ml; sheep polyclonal anti-human pepsinogen II (Abcam) diluted 1:100; 
mouse monoclonal anti–H+K+ ATPase β subunit (Abcam, ab2866) 
diluted 1:2,000; rabbit polyclonal anti-TFF1 and TFF2 (custom gen-
erated) (60) diluted 1:750 and 1:1,000, respectively; mouse monoclo-
nal anti-MUC5AC-biotin conjugate (Abcam, ab79082) diluted 1:400; 
rabbit monoclonal anti-CDX2-Alexa Fluor 488 conjugate (Abcam, 
ab195007) diluted 1:200; and chicken polyclonal anti-β-gal (Abcam, 
ab9361) diluted 1:200. Immunofluorescent detection of bound pri-
mary antibodies was achieved using the following secondary antibody 
conjugates: donkey anti-rabbit IgG-Alexa Fluor 594, goat-anti mouse 
IgG Alexa Fluor 488, streptavidin-Alexa Fluor 488, streptavidin-Alexa 
Fluor 568, and anti-sheep IgG Alexa Fluor 594 (all from Invitrogen 
transgenic overexpressing mice or following IL-11/gp130/STAT3 
hyperactivation (see Figure 1F) suggest a mechanism of negative 
transcriptional regulation via proinflammatory cytokine signal-
ing. This is corroborated by earlier work showing transcriptional 
repression of a GKN2 promoter-reporter construct induced by 
exogenous IL-1β, IL-6, and TNF-α treatment or NF-κB cotrans-
fection in cultured GECs (56). The appropriate expression dos-
age of GKN2 protein (and associated antiinflammatory activity) 
may therefore be governed by promoter cis elements, function-
ing collectively as a cytokine-responsive “transcriptional rheo-
stat.” Such a mechanism could explain the progressive loss of 
GKN2, in concert with worsening inflammation, as well as the 
recovery of GKN2 expression after H. pylori eradication and res-
toration of mucosal homeostasis (12).
In summary, we demonstrate an antiinflammatory role for 
the gastric epithelial-secreted protein, GKN2. We provide the first 
in vivo functional evidence to our knowledge that loss of GKN2 
expression, leading to deregulated Th1 immunity and exacer-
bation of inflammatory pathology, plays a causal role in GC pro-
gression. Critically, we have also shown that restoration of human 
GKN expression can interrupt gastric tumor growth in vivo. Cur-
rent preventative therapy for GC is based on antibiotic eradication 
of H. pylori (57). Our findings suggest complementation of GKN2 
function as an alternative disease management strategy, particu-
larly in the approximately 20% of infected individuals for whom 
antibiotic treatment fails (57) or in those presenting with irrevers-
ible premalignant disease (58).
Methods
Human tissues. H. pylori–infected and disease-free human gastric epi-
thelial tissues, GCs, and premalignant “adjacent-to-cancer” tissues 
with intestinal metaplasia were obtained endoscopically (59, 60).
Gene targeting. Embryonic stem cell clones (C57BL/6NTac genetic 
background) carrying a VelociGene lacZ reporter/loxP-flanked neo-
mycin selection cassette (61) at the Gkn2 locus were purchased from 
the Knockout Mouse Project repository (https://www.komp.org/). 
Injection of targeted embryonic stem cell clones into BALB/c recipi-
ent blastocysts and backcrossing (C57BL/6) of resulting chimeric mice 
to generate Gkn2+/– mice was performed at the Australian Phenomics 
Network laboratories, Monash, Clayton, Victoria, Australia (http://
www.australianphenomics.org.au/).
Generation of BAC transgenic mice. A 152-kb DNA fragment con-
taining the human GKN1 and GKN2 genomic region was excised from 
a BAC clone (RP11-H2112) by NotI digestion and then purified from 
the vector backbone by pulsed field gel electrophoresis through a 1% 
agarose, Tris/borate/EDTA gel. Purified BAC DNA was subjected 
to tube dialysis against 500 volumes TE buffer (10 mM Tris, 1 mM 
EDTA) overnight at 4°C, followed by microdialysis on 0.05-μm filters 
(Millipore) against 100 volumes microinjection buffer (10 mM Tris-
HCl, pH 7.5, 100 mM NaCl, 0.1 mM EDTA, 30 μM spermine, 70 μM 
spermidine) overnight at 4°C. Dialyzed BAC DNA was diluted to a con-
centration 0.5 ng/μl and then used for microinjection into C57BL/6J × 
DBA/2J F2 hybrid zygotes. BACTg founder animals were identified by 
PCR and Southern blotting analysis. Two founder lines (lines 5 and 9) 
with high-level expression of human GKNs were selected and back-
crossed to the C57BL/6 strain for 6 generations prior to commence-
ment of experiments. To generate BACTg gp130F/F compound trans-
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data or a Mann-Whitney U test for nonparametric data. P values of 
0.05 or lower were considered statistically significant.
Study approval. Mouse experiments were approved by the Murdoch 
Children’s Research Institute Animal Ethics Committee (approval no. 
A693, A700, and A713). Approval for experiments on human tissues was 
obtained from the Royal Melbourne Hospital Human Research Ethics 
Committee (approval no. 2004.176) and the Kanazawa University Eth-
ics Committee for Human Genome Research (approval no. 174.2008). 
Written informed consent was obtained for all study participants.
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Molecular Probes) and goat anti-chicken IgY-DyLight 488 (Abcam, 
ab96947). Samples were mounted in Pro-Long Gold medium contain-
ing DAPI counterstain (Invitrogen). Fluorescence images were cap-
tured using a Zeiss LSM 780 laser scanning confocal microscope and 
processed using ZEN software (Zeiss).
Flow cytometry. Cell suspensions were prepared from whole stom-
ach tissue using Gentle MACS lamina propria dissociation reagents 
and protocols (Miltenyi Biotech). Total leukocytes were purified from 
cell suspensions by Percoll (GE Healthcare) density gradient centrifu-
gation (40%/80% Percoll interface) and then resuspended in 2% FBS, 
2 mM EDTA in HBSS. Purified leukocytes were stained for presence of 
surface markers specific to macrophages, DCs, and MDSCs using the 
following anti-mouse monoclonal antibodies: CD11b (Brilliant Violet 
421 101235 [1:1,000]; PE 557397 [1:500]), CD49d (FITC, 103605 
[1:1,000]), Gr1 (PerCP-Cy5.5, 552093 [1:1,000]), Ly6C (PerCP, 
128028 [1:1,000]), F4/80 (Alexa Fluor 700, 123130 [1:1,000]), Ly6G 
(APC/Cy7, 127624 [1:500]), and CD45 (V500, 561487 [1:500]) (all 
Biolegend) and CD11c (APC, 17-0114-82 [1:1,000]) (eBioscience). 
Tregs were detected using the Mouse Regulatory T Cell Staining Kit 
(eBioscience, 88-8111-40): CD4 (FITC [1:500]), CD25 (APC [1:500]), 
and Foxp3 (PE [1:200]). CountBright absolute counting beads (Molec-
ular Probes) were used to determine total cell number per sample. Cell 
viability was assessed by propidium iodide dye exclusion. Leukocytes 
were gated based on forward and side scatter properties, with subse-
quent gating on specific myeloid cell markers as described above (gat-
ing strategies are shown in Supplemental Figure 12). Data collection 
was performed on a BD LSR II Flow Cytometer, and analysis was per-
formed using FACSDiva software (both BD Biosciences).
Gene expression. QRT-PCR was performed as described previously 
(66). Primer sequences were designed using the primer3 tool (http://
frodo.wi.mit.edu/primer3/) and are listed together with cycling 
parameters in the Supplemental Methods. Relative gene expression 
was normalized to expression of internal reference gene GAPDH 
(human) or Rpl32 (mouse) using the –2ΔΔCt method, where –2ΔΔCt = 
ΔCt sample – ΔCt calibrator (67).
Statistics. Data were analyzed with GraphPad Prism V5.1 soft-
ware. Data are presented as the mean ± SEM. Statistical analysis was 
performed by 1-way analysis of variance, with 2-group comparisons 
tested post hoc, using a 1- or 2-tailed Student’s t test for parametric 
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